Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system

Multiple Sclerosis

Volumn 4, Issue 1, 1998, Pages 39-44

  Trojano, M ^a   Avolio, C ^a   Ruggieri, M ^a   De Robertis, F ^a   Giuliani, F ^a   Paolicelli, D ^a   Livrea, P ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Blood brain barrier; Blood nerve barrier; Corticosteroids; Guillain Barre syndrome; Multiple sclerosis; Recombinant Interferon beta Ib; Soluble intercellular adhesion molecule I

Indexed keywords

CORTICOSTEROID; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON BETA SERINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; DEMYELINATING DISEASE; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL NEUROPATHY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031908176     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859800400110     Document Type: Article

References (50)

1. Raine CS. (1994) The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 36 (suppl): S61-S72.
2. Hughes RCA. (1990) The Guillain-Barré syndrome. London: Springer.
3. Hawkins CP et al. (1990) Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 113: 365-378.
4. Hartung HP et al. (1988) Immune mechanisms in inflammatory polyneuropathy. Ann NY Acad Sci 540: 122-161.
5. Hartung HP. (1993) Immune-mediated demyelination. Ann Neurol 33: 563-567.
6. Pober JS et al. (1986) Overlapping patterns of activation of human endothelial cells by interleukin-1, tumor necrosis factor and immune interferon. J Immunol 137: 1893-1896.
7. Fabry Z et al. (1992) Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55. J Neuroimmunol 36: 1-11.
8. Wong D, Dorovini-Zis K. (1992) Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide. J Neuroimmunol 39: 11-22.
9. Giovannoni G, Hartung HP. (1996) The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Opin Neurol 9: 165-177.
10. Hartung HP. (1995) Circulating adhesion molecules and inflammatory mediators in demyelination: A review. Neurology 45 (suppl 6): S22-S32.
11. Cannella B, Raine CS. (1995) The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37: 424-435.
12. Morrisey SP et al. (1996) Partial inhibition of AT-EAE by an antibody to ICAM-1: clinico-histological and MRI studies. J Neuroimmunol 69: 85-93.
13. Cannella B, Cross AH, Raine CS. (1993) Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis. J Neuroimmunol 46: 43-56.
14. Archelos JJ et al. (1993) Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 34: 145-154.
15. Hartung HP, Pollard JD, Harvey GK, Toyka KV. (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part I. Muscle Nerve 18: 137-153.
16. Archelos JJ et al. (1993) Suppression of experimental autoimmune neuritis by antibodies to the intercellular adhesion molecule-1. Brain 116: 1043-1058.
17. Stoll G et al. (1993) Macrophages and endothelial cells express intercellular adhesion molecule-1 in immunemediated demyelination but not in Wallerian degeneration of the rat peripheral nervous system. Lab Invest 68: 637-644.
18. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. (1991) A form of circulating ICAM-1 in human serum. J Immunol 147: 3788-3793.
19. Leeuwenberg JF et al. (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77: 543-549.
20. Vollmer T, Dalton J, Klotz K, Goldstein J. (1992) Astrocyte-lymphocyte binding: the role of immune cytokines and ICAM-1. Neurology 42 (suppl 3): 158-159.
21. Cannella B, Cross AH, Raine CS. (1990) Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system. J Exp Med 172: 162-170.
22. Trojano M et al. (1996) Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. Neurology 47: 1535-1541.
23. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. (1993) Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. Ann Neurol 33: 646-649.
24. Sharief MK et al. (1993) Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlations with TNF-alfa and blood-brain barrier damage. J Neuroimmunol 43: 15-21.
25. Hartung HP et al. (1993) Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 43: 2331-2335.
26. Rieckmann P et al. (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44: 2367-2372.
27. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. (1993) Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 43: 2679-2682.
28. Rieckmann P et al. (1993) Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol 47: 133-140.
29. Jander S, Heidenreich F, Stoll G. (1993) Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases. Neurology 43: 1809-1813.
30. Rieckmann P et al. (1995) Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 60: 9-15.
31. Dore-Duffy P et al. (1995) Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 37: 55-62.
32. Calabresi PA, Pelfrey CM, Tranquill LR and McFarland HF. (1996) Downregulation of VLA-4 on peripheral blood lymphocytes from multiple sclerosis patients treated with interferon beta-1b. Ann Neurol 40 (3): 553.
33. Soilu-Hänninen M, Salmi A, Salonen R. (1995) Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-γ-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol 60: 99-106.
34. Satoh J, Paty DW and Kim SU. (1995) Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology 45: 367-373.
35. Jiang H et al. (1995) Interferon β-1b reduces interferon γ-induced antigen-presenting capacity of human glial B cells. J Neuroimmunol 61: 17-25.
36. Barkof F, Hommes OR, Scheltens P and Valk J. (1991) Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 41: 1219-1222.
37. Miller DH et al. (1992) High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 55: 450-453.
38. Stone LA et al. (1995) The effect of Interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37: 611-619.
39. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocol. Ann Neurol 13: 227-231.
40. Kurtzke JF. (1983) Rating neurologic impairment in Multiple Sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
41. Asbury AK, Cornblath DR. (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27 (suppl): S21-S24.
42. Hughes RAC, Newson-Davis JM, Perkin GD, Pierce JM. (1978) Controlled trial of prednisolone in acute polyneuropathy. Lancet ii: 750-753.
43. Tibbling G, Link H, Ohman S. (1977) Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977; 37: 385-390.
44. Martin S et al. (1995) Circulating form of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1. J Immunol 154: 1951-1955
45. Guillain Barré Syndrome Steroid Trial Group. (1993) Double-blind trial of intravenous methylprednisolone in Guillain Barré Syndrome. Lancet 341: 586-590.
46. Rees J. (1995) Guillain Barré Syndrome. Clinical manifestations and directions for treatments. Drugs 49 (6): 912-920.
47. Arnason BGW. (1993) Interferon beta in multiple sclerosis. Neurology 43: 641-643.
48. Noronha A, Toscas A and Jensen MA. (1990) Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 27: 207-210.
49. Roep BO et al. (1994) Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus. The Lancet 343: 1590-1593.
50. van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. (1990) The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation resting T cells. J Immunol 144: 4579-4586.